1. Home
  2. ENTX vs GAN Comparison

ENTX vs GAN Comparison

Compare ENTX & GAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • GAN
  • Stock Information
  • Founded
  • ENTX 2010
  • GAN 1999
  • Country
  • ENTX Israel
  • GAN United States
  • Employees
  • ENTX N/A
  • GAN N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • GAN Computer Software: Programming Data Processing
  • Sector
  • ENTX Health Care
  • GAN Technology
  • Exchange
  • ENTX Nasdaq
  • GAN Nasdaq
  • Market Cap
  • ENTX 90.2M
  • GAN 83.2M
  • IPO Year
  • ENTX 2018
  • GAN 2020
  • Fundamental
  • Price
  • ENTX $2.43
  • GAN $1.75
  • Analyst Decision
  • ENTX Strong Buy
  • GAN
  • Analyst Count
  • ENTX 1
  • GAN 0
  • Target Price
  • ENTX $10.00
  • GAN N/A
  • AVG Volume (30 Days)
  • ENTX 83.2K
  • GAN 262.8K
  • Earning Date
  • ENTX 03-07-2025
  • GAN 03-12-2025
  • Dividend Yield
  • ENTX N/A
  • GAN N/A
  • EPS Growth
  • ENTX N/A
  • GAN N/A
  • EPS
  • ENTX N/A
  • GAN N/A
  • Revenue
  • ENTX $99,000.00
  • GAN $134,024,000.00
  • Revenue This Year
  • ENTX N/A
  • GAN $12.70
  • Revenue Next Year
  • ENTX N/A
  • GAN $10.67
  • P/E Ratio
  • ENTX N/A
  • GAN N/A
  • Revenue Growth
  • ENTX 607.14
  • GAN N/A
  • 52 Week Low
  • ENTX $0.95
  • GAN $1.17
  • 52 Week High
  • ENTX $3.35
  • GAN $1.90
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 54.06
  • GAN 36.04
  • Support Level
  • ENTX $2.21
  • GAN $1.72
  • Resistance Level
  • ENTX $2.62
  • GAN $1.85
  • Average True Range (ATR)
  • ENTX 0.21
  • GAN 0.04
  • MACD
  • ENTX -0.01
  • GAN -0.01
  • Stochastic Oscillator
  • ENTX 69.35
  • GAN 16.67

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About GAN GAN Limited

GAN Ltd provides Software-as-a-Service solutions for online casino gaming and sports betting applications. The company has two operating segments B2B and B2C. The B2B segment develops, markets, and sells instances of GameSTACK, GAN Sports, and iSight Back Office technology that incorporates comprehensive player registration, account funding, and back-office accounting and management tools that enable the casino operators to efficiently, confidently, and effectively extend their presence online in places that have permitted online real money gaming, and The B2C segment, which includes the operations of Coolbet, develops and operates a B2C online sports betting and casino platform that is accessible through its website in markets across Northern Europe, Latin America, and Canada.

Share on Social Networks: